Haematology

2018/06/24MEDICAL UPDATE

EHA 2018: OPTIMISMM

(Author: Maria Dalby; Interviewer: Esther Drain) Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd) in MM patients with 1-3 prior lines of therapy and a minimum of two cycles of lenalidomide treatment.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: Immunotherapy in MM: why, when and how?

(Author: Maria Dalby; Interviewer: Esther Drain) The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and adoptive cellular therapies. In an educational session at EHA 2018 Dr Niels van de Donk from Amsterdam outlined the importance of immunotherapy in the treatment of MM now and in the future, focussing especially the role of antibody combinations in the upfront setting and the promise of CAR-T cell therapy.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: The Issue of Frailty in MM

(Author: Maria Dalby; Interviewer: Esther Drain) When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a medical need for maximising tolerability and optimising efficacy in elderly patients by individualising therapy based on fitness rather than chronological age. Professor Sonja Zweegman from Amsterdam hosted a Meet the Expert session at EHA 2018 which highlighted some of the challenges around detecting and assessing frailty and adapting therapy so that frail patients can achieve the best possible outcome.

READ MORE

2018/06/24MEDICAL UPDATE

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

(Author: Maria Dalby; Interviewer: Esther Drain) The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in some cases even to the extent that it can be described as a cure. However, optimisation of second-line therapy and beyond continues to challenge clinicians in the novel therapy era. In his presentation at a Scientific Working Group session at EHA 2018, Professor Hartmut Goldschmidt from Heidelberg in Germany reviewed strategies for treating MM patients who are eligible and ineligible for stem cell transplantation, respectively.

READ MORE

2018/05/11MEDICAL UPDATE

BSH 2018: Debate: CAR-T cell therapy will become the standard of care for relapsed high-grade B-cell lymphoma within 5 years

By Christine Clark (article) and Alex Burton (interviews) Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is complex to administer and offers little outcome advantage?...

READ MORE

2018/05/11MEDICAL UPDATE

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

By Maria Dalby (article) and Esther Drain (interviews) Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active DCs can be grown ex vivo from peripheral blood mononuclear cells in the presence of cytokines and can be made to carry tumour antigens to stimulate an anti-tumour response…

READ MORE

2018/05/11MEDICAL UPDATE

BSH 2018: Stratified medicine – using genomic analysis to deliver therapy in high-risk myeloma

By Maria Dalby (article) and Esther Drain (interviews) Dr Martin Kaiser (London) discusses recent work from the UK on identifying robust markers and how clinical decisions can be made according to the biology of the disease. Advances in the management of multiple myeloma (MM) in recent years have drastically improved survival compared with 40-50 years ago. However, unlike other haematological cancers such as HL and DLBCL, MM remains incurable with a high likelihood of relapse and death...

READ MORE

2017/09/30MEDICAL UPDATE

ICML 2017: Response-adapted therapy for Hodgkin’s lymphoma

Professor Peter Johnson (Southampton, UK) tells us what's new with response-adapted therapy and what are the benefits to patients. [embed]http://vimeo.com/226290495[/embed]

READ MORE

2017/07/11MEDICAL UPDATE

ICML 2017: How will Hodgkins lymphoma be managed in 2020?

By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but different interpretations can also be applied to study results to advocate different approaches.

READ MORE

2017/04/24MEDICAL UPDATE

BSH 2017: Management of Asymptomatic Follicular Lymphoma

The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma is curable in some cases …

READ MORE